anonymous
Guest
anonymous
Guest
spot on until Otezla. didn’t overpay a little, overpaid by 3-4B, what’s troubling is our history of poor acquisitions and inability to develop innovative drugs. If we want to hold the sales team accountable that’s fine, but where is the accountability for the executive team? Outside of price increases and expense cuts what has Bob delivered?
Do you realize we get over two billion in tax benefits from it? So reduce purchase price by $2.2 billion. Clearly you're not paying attention. Which other acquisitions were bad? Kyprolis was good if we developed it right. Good acquisition by development once acquired and poor execution. The acquisition assumed a Frontline indication which our shitty development never got. What else you got? I agree Amgen R&D blows.